Provided by Tiger Trade Technology Pte. Ltd.

Array Digital Infrastructure Inc.

38.12
+0.07000.18%
Post-market: 38.120.00000.00%19:30 EDT
Volume:187.41K
Turnover:7.14M
Market Cap:3.29B
PE:6.16
High:38.36
Open:38.29
Low:37.75
Close:38.05
52wk High:60.82
52wk Low:33.71
Shares:86.38M
Float Shares:15.56M
Volume Ratio:0.72
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.19
EPS(LYR):0.5551
ROE:22.68%
ROA:0.02%
PB:2.60
PE(LYR):68.68

Loading ...

Earning Preview: Array Digital Infrastructure Inc. Q2 revenue is expected to decrease by 94.24%, and institutional views are cautious

Earnings Agent
·
Aug 01

Array Digital Infrastructure Schedules Quarterly Results Conference Call

Reuters
·
Jul 31

Array Digital Infrastructure Inc Expected to Post Earnings of 62 Cents a Share - Earnings Preview

Reuters
·
Jul 30

Incyte says EC approves Opzelura cream for treatment of AD

TIPRANKS
·
Jul 29

FAA proposes to adopt new AD for Boeing planes, to inspect seat installation

TIPRANKS
·
Jul 28

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

GlobeNewswire
·
Jul 28

T-mobile US Inc. Stock Advances 5.7%, Outperforms Market

Dow Jones
·
Jul 25

T-mobile US Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 21

T-mobile US Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 17

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

GlobeNewswire
·
Jul 15

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment

GlobeNewswire
·
Jul 14

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

GlobeNewswire
·
Jul 14

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

GlobeNewswire
·
Jul 13

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026

GlobeNewswire
·
Jul 12

RBC Capital Sticks to Its Hold Rating for Array Digital Infrastructure (AD)

TIPRANKS
·
Jul 11

T-mobile US Inc. Stock Climbs 3.4%, Outperforms Peers

Dow Jones
·
Jul 11

Array Digital Infr is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Jul 10

Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026

GlobeNewswire
·
Jul 08

Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research

GlobeNewswire
·
Jul 07

CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026

GlobeNewswire
·
Jul 06